Mounjaro Weight-Loss Drug Set for NHS Rollout; Users Share Experiences

The weight-loss medication Mounjaro is scheduled for introduction on England’s National Health Service starting in March. This drug is among several weight-loss treatments that have gained significant popularity recently, available for private purchase through clinics and pharmacies. BBC News interviewed individuals currently paying for Mounjaro or those anticipating NHS access, to gather their perspectives on this development. Alix Harvey, a 35-year-old marine biologist residing in Plymouth, expressed approval for the initiative to broaden availability of the weight-loss medication. She began using Mounjaro in May, having experienced difficulties with weight accumulation subsequent to giving birth to her two children. She stated, “I got to the stage where I went ‘if this continues, I’m going to end up morbidly obese in my late 30s’.” Over the past six months, her body mass index (BMI) decreased from 32 to 22, and she shed 25% of her total body weight. The NHS defines individuals with a BMI of 25 or higher as overweight, and those with a BMI of 30 or higher as obese. “It’s changed my life… It’s completely changed my attitude to food,” she remarked, further noting that she felt encouraged to attend the gym and engage in weightlifting. Explaining that Mounjaro functions as an appetite suppressant, she mentioned her initial difficulty consuming over 1,000 calories, though the effects had since “decreased” and her appetite had returned. Ms. Harvey has been spending approximately £170 monthly on the medication, but stated that she has saved an equivalent sum by purchasing less food and drink, and intends to discontinue its use. Under the NICE guidelines, she would not qualify for the drug, as these guidelines specify that Mounjaro will be provided to individuals with a BMI exceeding 35 and experiencing at least one health issue linked to obesity. However, she advocates for a phased implementation to guarantee that adequate support systems are established concurrently with the drug, given the potential for users to regain weight upon cessation of treatment. She commented, “It’s not a quick fix.” She added, “Having that maintenance plan for afterwards for supporting people to keep that weight off afterwards is really vital.” Jane Graham, a cardiac physiologist based in York, expressed her desire to obtain a weight-loss injection via the NHS to shed two stone (12.7kg). The 60-year-old experienced a heart attack nine years prior and, in addition to facing a high risk of subsequent heart attacks, is pre-diabetic. She stated, “My arms and legs aren’t fat, just the middle of my body – which is where the risks [for heart-related health issues] lie.” She continued, “My waist is 42 inches [106cm] but I weigh 12 stone [76.2kg] and I can’t get it off.” Ms. Graham indicated that she had “tried everything” to reduce her weight, encompassing the calorie-restricted 5:2 diet and extensively reading nutrition books “until I’m blue in the face”. “The fight’s gone out of me because I’ve tried for so long,” she commented, but also mentioned being “worried” about a potential deterioration of her health conditions. Although she desires to try Mounjaro, she prefers medical supervision within the NHS program because of her existing health conditions. She explained, “I would be quite happy to pay for it but be supervised, but you can’t do that. It’s either one or the other.” She expressed profound disappointment that, with a BMI of 30, she will not meet the eligibility criteria for the drug according to NICE guidelines. Furthermore, even if she were to satisfy the eligibility requirements, Ms. Graham harbored concerns regarding the potential waiting period to obtain Mounjaro. “By the time I’ve waited 12 years… I’ll be 72 and whatever is going to happen to me will have happened. It’s going to be too late,” she stated. NICE has granted the NHS over ten years for the drug’s implementation, citing worries that it could strain existing services. Professor Jonathan Benger, NICE’s chief medical officer, conceded that this approach would result in “many people would have to wait”. He further commented, “We’ve had to make this difficult decision in order to protect vital NHS services and also to test ways of delivering this new generation of weight-loss medications.” Paul, who chose not to disclose his surname, and his wife have been using Mounjaro for several months, having acquired it from a private online clinic. He remarked, “My wife and I don’t drink, don’t smoke but we do like to eat and we were both very overweight.” His wife has achieved a weight loss of 5 stone (31.7kg) since commencing treatment in July, and Paul indicated that he too has lost weight since beginning in October. Paul, who mentioned his peak weight was 20 stone (127kg), stated that he had “tried everything” in an attempt to lose weight. “But I found the weight would just not come off. It was demoralising,” he commented. He mentioned consulting his GP but opted to try Mounjaro after learning of positive outcomes. Paul stated that the medication had assisted in silencing the “food voice” that constantly indicated hunger. His wife incurs a monthly cost of £180 for a private prescription, and he has been utilizing some of her medication – as she requires less after losing weight – because they cannot afford for him to purchase his own as well. Paul has not sought professional advice regarding the sharing of prescription medication, an act that is potentially hazardous and discouraged. Paul expressed that NHS provision would be beneficial, but deemed a 12-year waiting period for some individuals as “too long”. He acknowledges the risk associated with taking medication not specifically prescribed for him and has encountered some mild side effects. He further added, “It’s a bit of a punt. I will go back to my GP for a general check up at some point and let them know that I am on it.”